Financials

  • Market Capitalization 3.87 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-7.9
Price to sales ratio

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
1508
ADPT
Adaptive Biotechnologies Corporation - Common Stock
25.19 USD-4.73%-1.72%+13.47%+45.94%4.02 B USD
1518
TNGX
Tango Therapeutics, Inc. - Common Stock
23.34 USD-7.67%-1.10%-11.46%+253.10%3.94 B USD
1533
IDYA
IDEAYA Biosciences, Inc. - Common Stock
40.11 USD-3.97%+1.08%+12.99%+23.11%3.87 B USD
1541
DNLI
Denali Therapeutics Inc. - Common Stock
24.00 USD-2.72%-3.54%0.00%+48.42%3.84 B USD

Frequently asked questions about Amylyx Pharmaceuticals, Inc. Common Stock

What is the Amylyx Pharmaceuticals, Inc. Common Stock stock price today?

The current price of Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is 34.74. Over the past 24 hours, the stock has changed by -6.56%. Follow the AMLX chart for real-time price dynamics.

What is the stock ticker of Amylyx Pharmaceuticals, Inc. Common Stock?

Amylyx Pharmaceuticals, Inc. Common Stock trades under the ticker AMLX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Amylyx Pharmaceuticals, Inc. Common Stock stock going up?

AMLX has changed by -10.09% over the last week, +76.43% over the last month, and +277.61% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Amylyx Pharmaceuticals, Inc. Common Stock?

Amylyx Pharmaceuticals, Inc. Common Stock currently has a market capitalization of 3.87 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does Amylyx Pharmaceuticals, Inc. Common Stock release financial reports?

Yes. You can track Amylyx Pharmaceuticals, Inc. Common Stock financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What were Amylyx Pharmaceuticals, Inc. Common Stock earnings last quarter?

Last quarter, Amylyx Pharmaceuticals, Inc. Common Stock reported earnings of -0.39 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Amylyx Pharmaceuticals, Inc. Common Stock revenue for the last quarter?

Amylyx Pharmaceuticals, Inc. Common Stock reported quarterly revenue of 0. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Amylyx Pharmaceuticals, Inc. Common Stock net income for the last quarter?

Amylyx Pharmaceuticals, Inc. Common Stock reported net income of -43.42 M for the last quarter. The previous quarter showed -41.28 M, which means net income changed by -5.18%.

How many employees does Amylyx Pharmaceuticals, Inc. Common Stock have?

As of the latest available data, Amylyx Pharmaceuticals, Inc. Common Stock has 136 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Amylyx Pharmaceuticals, Inc. Common Stock stock?

You can buy Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Amylyx Pharmaceuticals, Inc. Common Stock stock?

Investing in Amylyx Pharmaceuticals, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the AMLX chart and related analysis on metatrader.com as part of your research.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

News